GENE ONLINE|News &
Opinion
Blog

2025-11-28|

Early-Life RSV Infections Linked to Higher Childhood Asthma Risk, Study Finds

by GOAI
Share To

Belgian researchers from VIB and Ghent University, in collaboration with Danish scientists, have identified a strong link between early-life respiratory syncytial virus (RSV) infections and an increased risk of developing childhood asthma. Their findings, published in *Science Immunology*, indicate that infants who contract RSV are more likely to develop asthma later in life, particularly if they have a family history of allergies or asthma. The study suggests that vaccinating newborns against RSV could potentially reduce the prevalence of asthma in children.

The research highlights the significant impact of RSV on respiratory health during infancy. The team found that early exposure to the virus may play a critical role in triggering asthma development, especially among genetically predisposed children. These findings underscore the potential benefits of preventive measures, such as RSV vaccination, to mitigate long-term respiratory conditions. The study provides new insights into how early viral infections influence immune responses and their connection to chronic diseases like asthma.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top